A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Phase 2
Completed
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 3
- Registration Number
- NCT04179409
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
Spironolactone Versus Prednisolone in DMD
Phase 1
Terminated
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03777319
- Locations
- ๐บ๐ธ
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
๐บ๐ธNationwide Children's Hospital, Columbus, Ohio, United States
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03333590
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Phase 1
Withdrawn
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Biological: rAAVrh74.MCK.GALGT2Other: PLACEBO (Saline)
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Kevin Flanigan
- Registration Number
- NCT02704325
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath